MICHAEL SWIT has been solving vital legal and regulatory issues since 1984. Before relaunching his FDA law practice in 2017, he served for three years at Illumina, the leader in gene sequencing technology, as its chief regulatory counsel. Prior to that, Swit was in the FDA Law Practices at three global law firms, served as a vice president at The Weinberg Group, a premier regulatory consultancy, and was general counsel of Par Pharmaceutical, a major generic drug maker. He earned his AB, magna cum laude, with high honors in history, at Bowdoin College, and his law degree at Emory University